Gene · 5598
Papers3,971
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,971
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Roles of autophagy-related genes in the therapeutic effects of Xuanfei Pingchuan capsules on chronic obstructive pulmonary disease based on transcriptome sequencing analysis. | Front Pharmacol | 2023 | 37274101 | PubTator, text mining | PubMed |
| A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas. | Mater Today Bio | 2023 | 37273792 | PubTator, text mining | PubMed |
| Molecular dynamic simulation reveals the molecular interactions of epidermal growth factor receptor with musk xylene are involved in the carcinogenicity. | RSC Adv | 2023 | 37266509 | PubTator, text mining | PubMed |
| An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. | Circ Res | 2023 | 37264926 | PubTator, text mining | PubMed |
| Author Correction: Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response. | Exp Mol Med | 2023 | 37264203 | PubTator, text mining | PubMed |
| Erk5 functions in modulation of zebrafish intestinal permeability. | Cell Tissue Res | 2023 | 37256363 | PubTator, text mining | PubMed |
| MicroRNA-372 acts as a double-edged sword in human cancers. | Heliyon | 2023 | 37251909 | PubTator, text mining | PubMed |
| Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects. | Acta Pharm Sin B | 2023 | 37250154 | PubTator, text mining | PubMed |
| β-Sitosterol as a Promising Anticancer Agent for Chemoprevention and Chemotherapy: Mechanisms of Action and Future Prospects. | Adv Nutr | 2023 | 37247842 | PubTator, text mining | PubMed |
| Therapeutic and diagnostic applications of exosomal circRNAs in breast cancer. | Funct Integr Genomics | 2023 | 37243750 | PubTator, text mining | PubMed |
| Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Adenocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Suppressing AKT. | Pharmaceuticals (Basel) | 2023 | 37242538 | PubTator, text mining | PubMed |
| The Antioxidant Effect of Dietary Bioactives Arises from the Interplay between the Physiology of the Host and the Gut Microbiota: Involvement of Short-Chain Fatty Acids. | Antioxidants (Basel) | 2023 | 37237938 | PubTator, text mining | PubMed |
| Novel trajectories of the NK1R antagonist aprepitant in rotenone-induced Parkinsonism-like symptoms in rats: Involvement of ERK5/KLF4/p62/Nrf2 signaling axis. | Chem Biol Interact | 2023 | 37224993 | PubTator, text mining | PubMed |
| Drug-drug synthetic lethality to combat cancer: From bench to bedside. | Clin Transl Med | 2023 | 37218919 | PubTator, text mining | PubMed |
| Iron metabolism and ferroptosis in diabetic bone loss: from mechanism to therapy. | Front Nutr | 2023 | 37215218 | PubTator, text mining | PubMed |
| Helicobacter pylori regulates stomach diseases by activating cell pathways and DNA methylation of host cells. | Front Cell Dev Biol | 2023 | 37215092 | PubTator, text mining | PubMed |
| New small molecules in dermatology: for the autoimmunity, inflammation and beyond. | Inflamm Res | 2023 | 37212867 | PubTator, text mining | PubMed |
| Kinases in cerebral cavernous malformations: Pathogenesis and therapeutic targets. | Biochim Biophys Acta Mol Cell Res | 2023 | 37209718 | PubTator, text mining | PubMed |
| Apolipoprotein ε in Brain and Retinal Neurodegenerative Diseases. | Aging Dis | 2023 | 37199411 | PubTator, text mining | PubMed |
| Cooperation between Prostaglandin E2 and Epidermal Growth Factor Receptor in Cancer Progression: A Dual Target for Cancer Therapy. | Cancers (Basel) | 2023 | 37190301 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5598/papers?page=19